Form 4: Rallybio Corp Director Helen M Boudreau Reports Stock Option Grant

Director Helen M Boudreau reports the grant of stock options in Rallybio Corp.

Summary

• On May 13, 2025, Helen M Boudreau, a director of Rallybio Corp, was granted an option to purchase 28,500 shares of common stock.
• The exercise price of the option is $0.3.
• The option vests on the earlier of May 13, 2026, or the date of the company's 2026 Annual Meeting of Stockholders.
• The option expires on May 13, 2035.
• Following the transaction, Boudreau directly owns 28,500 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a standard compensation practice that aligns director interests with shareholder value.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.

Industry Context

This is a standard practice for incentivizing board members in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, especially in the biotechnology sector.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparable companies in the biotech space, such as BioNTech or Moderna, also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's actions lead to improved company performance.

Key Dates

Keywords

Rallybio Corp, RLYB, Helen M Boudreau, Director, Stock Option, Equity Incentive Plan, Form 4, Beneficial Ownership